discovery stage partnering terms and agreements in pharma and biotech

ReportLinker Find Industry reports, Company profilesand Market Statistics

>> Get this Report Now by email!

Discovery Stage Partnering Terms and Agreements in Pharma and

Biotech

Published on February 2014

Report Summary

Provides comprehensive understanding and unprecedented access to the discovery stage partnering agreements entered into by the

worlds leading biopharma companiesThe Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides

comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the

worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter discovery stage partnering deals. The

majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals

tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in

terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the

payments clauses, the devil is in the detail in terms of how payments are triggered ' contract documents provide this insight where

press releases do not.

This report contains over 4,000 links to online copies of actual discovery stage deals and contract documents as submitted to the

Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions

about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each

party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of discovery stage deal making and business activities. Chapter 1 provides an

introduction to the report, whilst chapter 2 provides an overview of why companies partner discovery stage compounds/products.

Chapter 3 provides an overview of discovery stage deals strategy and deal structure including numerous case studies. Chapter 4

provides an overview of the various payment strategies used in discovery stage deals.

Chapter 5 provides a review of discovery stage deal making since 2009. Deals are listed by headline value, signed by big pharma, big

biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides

online access to the contract.

Chapter 6 provides a detailed analysis of discovery stage payment terms including average headline, upfront, milestone and royalty

rates for discovery deals.

Chapter 7 provides a review of the leading discovery stage deal by headline value.

Chapter 8 provides a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a

comprehensive listing of discovery stage deals, as well as contract documents available in the public domain. Where available, each

deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on

demand.

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (From Issuu) /22

http://www.reportlinker.com?utm_campaign=plp&utm_source=issuu&utm_medium=referral



http://www.reportlinker.com/p01417156/Discovery-Stage-Partnering-Terms-and-Agreements-in-Pharma-and-Biotech.html#utm_campaign=plp&utm_source=issuu&utm_medium=referral




Chapter 9 provides a comprehensive and detailed review of discovery stage partnering deals signed and announced since 2009,

where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at

signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an

online version of the deal record and where available, the contract document, providing easy access to each contract document on

demand.

Chapter 10 provides a comprehensive directory of discovery stage partnering deals since 2009.

The report also includes numerous tables and figures that illustrate the trends and activities in discovery stage partnering and deal

making since 2009.

In addition, a comprehensive appendix is provided organized by partnering company A-Z , deal type, therapy focus and technology

type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing

easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development

and commercialization of discovery stage products and compounds.Discovery Stage Partnering Terms and Agreements in Pharma

and Biotech provides the reader with the following key benefits:

In-depth understanding of discovery stage deal trends since 2009

Access to headline, upfront, milestone and royalty data

Analysis of the structure of discovery stage agreements with numerous real life case studies

Detailed access to actual discovery stage deals entered into by the leading fifty big pharma and big biotech companies

Insight into the terms included in a discovery stage agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scopes

Discovery Stage Partnering Terms and Agreements Terms and Agreements in Pharm and Biotech is intended to provide the reader

with an in-depth understanding and access to discovery stage deal trends and structure of deals entered into by leading companies

worldwide.

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech includes:

Trends in discovery stage dealmaking in the biopharma industry since 2009

Analysis of discovery stage deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life discovery stage deals

Access to over 4,000 discovery stage deals

The leading discovery stage deals by value since 2009

Most active discovery stage dealmakers since 2009

The leading discovery stage partnering resources

In Discovery Stage Partnering Terms and Agreements in Pharm and Biotech, the available contracts are listed by:

Company A-Z

Headline value

Stage of development at signing









Deal type

Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy

access to each contract document on demand.

The Discovery Stage Partnering Terms and Agreements in Pharma and biotech report provides comprehensive access to available

deals and contract documents for over 4,000 discovery stage deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned'

What is actually granted by the agreement to the partner company'

What exclusivity is granted'

What is the payment structure for the deal'

How aresalesand payments audited'

What is the deal term'

How are the key terms of the agreement defined'

How are IPRs handled and owned'

Who is responsible for commercialization'

Who is responsible for development, supply, and manufacture'

How is confidentiality and publication managed'

How are disputes to be resolved'

Under what conditions can the deal be terminated'

What happens when there is a change of ownership'

What sublicensing and subcontracting provisions have been agreed'

Which boilerplate clauses does the company insist upon'

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type'

Which jurisdiction does the company insist upon for agreement law'

Table of Content

Executive Summary

Chapter 1 ' Introduction

Chapter 2 ' Why do companies partner at discovery stage'

2.1. Introduction

2.2. The role of discovery stage partnering

2.2.1. In-licensing at discovery stage

2.2.2. Out-licensing at discovery stage

2.3. Difference between discovery, preclinical and clinical stage deals

2.4. Reasons for entering into discovery stage partnering deals

2.4.1. Licensors reasons for entering discovery stage deals

2.4.2. Licensees reasons for entering discovery stage deals

2.5. The future of discovery stage partnering deals

Chapter 3 ' Discovery stage deal strategies and structure









3.1. Introduction

3.2. At what stage do companies partner'

3.2.1. Partnering early in pharmaceutical/biotech

3.2.1.1. Discovery and preclinical stage partnering case studies

3.2.1.1.a. Case study: LEO Pharma - 4SC

3.2.1.1.b. Case study: Heptares Therapeutics - Cubist

3.2.1.1.c. Case study: Pfizer - Repligen

3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec

3.2.2. Partnering later in pharmaceutical/biotech

3.2.2.1. Clinical stage partnering case studies

3.2.2.1.a. Case study: Roche ' Genentech - Chiasma

3.2.2.1.b. Case study: Teva ' Xenon Pharmaceuticals

3.2.2.1.c. Case study: AstraZeneca - Ardelyx

3.2.2.1.d. Case study: Baxter ' Onconova Therapeutics

3.3. Early and later stage partnering ' a risk/cost comparison

3.4. What do companies spend on discovery, preclinical and clinical stage partnering'

3.5. Pure versus multi-component partnering deals

3.6. Pure licensing agreement structure

3.6.1. Example pure licensing agreements

3.6.1.a. Case study : Coley Pharmaceutical ' Dynavax Technologies

3.6.1.b. Case study : Novartis ' Marina Biotech

3.7. Multicomponent discovery stage partnering agreements

3.7.1.a. Example multicomponent early stage clauses

3.7.1.a. Case study: Tracon 'Boehringer Ingelheim ' Macrogenics

3.7.1.b. Case study: Fibrocell Science ' Intrexon

Chapter 4 ' Discovery stage partnering payment strategies

4.1. Introduction

4.2. Discovery stage payment strategies

4.3. Payment options

4.3.1. Headline values

4.3.2. Upfront payments

4.3.2.1. Conditionality of upfront payments

4.3.3. Loans

4.3.4. Convertible loans

4.3.5. Equity

4.3.6. R&D funding

4.3.7. Licensing fees

4.3.8. Milestone payments

4.3.9. Royalty payments

4.3.9.1. Issues affecting royalty rates

4.3.9.2. Royalties on combination products

4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech

4.3.9.3. Guaranteed minimum/maximum annual payments

4.3.9.4. Royalty stacking

4.3.9.5. Royalties and supply/purchase contracts









4.3.10. Quids

4.3.11. Option payments

Chapter 5 ' Trends in discovery stage deal making

5.1. Introduction

5.2. Discovery stage partnering over the years

5.2.1.. Attributes of discovery deals

5.3. Big pharma discovery stage dealmaking activity

5.4. Big biotech discovery stage dealmaking activity

5.5. Discovery stage partnering by deal type

5.6. Discovery stage partnering by disease type

5.7. Discovery stage partnering by technology type

Chapter 6 ' Average payment terms for discovery stage partnering

6.1. Introduction

6.2. Guidelines for discovery stage payment terms

6.2.1. Upfront payments

6.2.2. Milestone payments

6.2.3. Royalty payments

6.3. Discovery stage payment terms ' deal data analysis

6.3.1. Public data

6.3.2. Survey data

6.4. Payment terms analysis

6.4.1. Discovery stage headline values

Figure 17: Discovery stage deals with a headline value- 2009





6.4.2. Discovery stage upfront payments

Figure 24: Discovery stage deals with upfront payment values- 2009

Figure 25: Discovery stage deals with upfront payment values' 2010




6.4.3. Discovery stage milestone payments

Figure 31: Discovery stage deals with milestone payments -2009





6.4.4. Discovery stage royalty rates

Figure 38: Discovery stage deals with royalty rates, %- 2009













Chapter 7 ' Leading preclinical stage deals

7.1. Introduction

7.2. Top discovery stage deals by value

Chapter 8 ' Big pharma and big biotech discovery stage partnering deals

8.1. Introduction

8.2. How to use big pharma/big biotech discovery stage partnering deals

8.3. Big pharma discovery stage partnering company profiles

Abbott

Allergan

Amgen

Astellas

AstraZeneca

Baxter International

Bayer

Bayer Animal Health

Bayer CropScience

Bayer Healthcare

Bayer Innovation

Bayer Schering Pharma

Bayer Technology Services

Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

CSL

CSL Biotherapies

Daiichi Sankyo

Dainippon Sumitomo

Eisai

Eisai Inc

Eli Lilly

Endo Pharmaceuticals

Fresenius

Fresenius Kabi Pharmaceuticals

Gilead Sciences

GlaxoSmithKline

Grifols

Johnson & Johnson

Johnson & Johnson Development Corporation

Johnson & Johnson Innovation

Johnson & Johnson Pharmaceutical Research Institute

Janssen-Cilag

Janssen Biotech

Janssen Pharmaceutica KK

Janssen Pharmaceutica NV

Janssen Pharmaceutical









Janssen Research & Development

Kyowa Hakko Kirin

Lundbeck

Merck & Co

Merck Sharpe & Dohme

Merck KGaA

Merck Serono

Mitsubishi Tanabe

Novartis

Novartis Institute for Tropical Diseases

Novartis Molecular Diagnostics

Novartis Venture Funds

Novo Nordisk

Otsuka

Pfizer

Pfizer Animal Health

Roche

Roche Applied Science

Roche Diagnostics

Roche Institute for Research and Translational Medicine

Roche Molecular Systems

Roche NimbleGen

Genentech

Sanofi

Sanofi-Aventis

Sanofi-Pasteur

Servier

Shionogi

Shire

Shire Human Genetic Therapies

Takeda

Takeda Cambridge

Takeda San Francisco

Teva

UCB

Valeant

Warner Chilcott

8.4. Big biotech discovery stage partnering company profiles

3SBio

Actelion

Alexion Pharmaceuticals

Array Biopharma

Bavarian Nordic

Biocon

Cangene

Cubist









Dendreon

Elan

Emergent BioSolutions

Galapagos

Genmab

Ipsen

Isis Pharmaceuticals

Morphosys

Onyx Pharmaceuticals

PDL BioPharma

Questcor Pharmaceuticals

Regeneron Pharmaceuticals

Seattle Genetics

United Therapeutics

Vertex Pharmaceuticals

Chapter 9 ' Discovery stage partnering contracts directory

9.1. Introduction

9.2. Company A-Z

ABT Holding Company

ACADIA Pharmaceuticals

Adamis Pharmaceuticals

Adeona Pharmaceuticals

Adimab

Advanced Cell Technology

Advaxis

Advirna

Agensys

Aldagen


Alimera Sciences

Alnylam Pharmaceuticals

Altman Enterprises

Ambit Biosciences

America Stem Cell

American Type Culture Collection (ATCC)

Amgen

Anacor Pharmaceuticals

Angiotech Pharmaceuticals

Antigenics

Applied Genetic Technologies

Arana Therapeutics

Arno Therapeutics

ArQule

Array Biopharma

Arrayit Diagnostics

Astellas Pharma









AstraZeneca

Asubio Pharma

Athersys

Atlantic Healthcare

Avalon Pharmaceuticals

AVEO Pharmaceuticals

AVI Pharma

Bayer Schering Pharma

BG Medicine

BIND Biosciences

BIND Therapeutics

Bio-Matrix Scientific

Bio-Path

Biocurex

Biogen Idec

BioTime

Biovail

BioWa

BioZone Laboratories


BrainStorm Cell Therapeutics


Buck Institute for Age Research

Cadila Pharmaceuticals

Cardiff University

Cardium Therapeutics

Catalyst Pharmaceutical Partners

Cedars-Sinai Medical Center

Celera

Celgene

Celladon

Centocor Ortho Biotech

CHA Bio & Diostech

Charleys Fund

CHDI Foundation

Chi-Fu Trading

Children's Hospital Boston

Chiva Pharmaceuticals

Clinical Data

Codexis

Cohen-McNiece Foundation

Columbia University

CombinatoRx

CorMedix

CPL Biologicals

Crucell

Cystic Fibrosis Foundation

Cytokinetics









Cytori Therapeutics

CytRx

Daiichi Sankyo

Dana-Farber Cancer Institute

DARA BioSciences

DeCODE Genetics

Defense Threat Reduction Agency

Delcath Systems

Department of Homeland Security

Dharmacon

DNA Biomedical Solutions

Dow AgroSciences

Dynavax Technologies

Edison Pharmaceuticals

Elanco

Eleven Biotherapeutics

Eli Lilly

Embryome Sciences

Emory University

Enanta Pharmaceuticals

Enox BioPharma

Entera Bio

Entest BioMedical

Enzon Pharmaceuticals

EPIX Pharmaceuticals

Exact Sciences

Exelixis

Fate Therapeutics

Fibrocell Science

Fraunhofer USA

Fudan University

Galena Biopharma

GE Healthcare

Gen-Probe

Genentech

Genoptix

GenVec

Genzyme

Geron

GlaxoSmithKline

GlobeImmune

GlycArt

Health Discovery

Heat Biologics

Henry M. Jackson Foundation

IBioPharma

Icagen

Ilypsa









ImaRX

ImmunoCellular Therapeutics

ImmunoGen

Infinity Pharmaceuticals

Inhibitex

Intellect Neurosciences

Intellikine

Intercept Pharmaceuticals

InterMune

Intrexon

Invivis Pharmaceuticals

Iogen Energy

Isis Pharmaceuticals

Janssen Pharmaceutica NV

Johns Hopkins University

Johnson & Johnson

Kaketsuken

KaloBios Pharmaceuticals

Karyopharm Therapeutics

Kraig Biocraft Laboratories

Lankenau Institute for Medical Research

Lexicon Pharmaceuticals

Ligand Pharmaceuticals

Lonza

Macrogenics

Marina Biotech

Marv Enterprises

Massachusetts General Hospital

Maxygen

MD Anderson Cancer Center

Medi-Pharmaceuticals

Merck and Co

Merrimack Pharmaceuticals

Metabasis Therapeutics

Micromet

Millennium

Multiple Myeloma Research Foundation

Nanshan Memorial Medical Institute

National Institute of Allergy and Infectious Diseases

National Institute of Diabetes and Digestive and Kidney Diseases

Neogenomics

Neurobiological Technologies

Neurocrine Biosciences

New York University

Newlink Genetics

Nitricare

Nitto Denko

Northwestern University









Novartis

Novavax

Novo Nordisk

Ohio State University

Omeros

Omnimmune

Opexa Therapeutics

Oragenics

Oramed Pharmaceuticals

Organon

Organovo

Orphazyme

Ortho-McNeil

OSI Pharmaceuticals

Ottawa Hospital Research Institute

Oxygen Biotherapeutics

Pacific BioScience of California

Pacific Biosciences

Palatin Technologies

Penwest Pharmaceuticals

Peregrine Pharmaceuticals

Perseid Therapeutics

Perugia University

Pfizer

Pharmacopeia

Poniard Pharmaceuticals

Premier Biomedical

Pro Pharmaceuticals

Prometheus

Protein Polymer Technologies

Proteonomix

Psynova Neurotech

Public Health Service

Quark Pharmaceuticals

Ramot at Tel Aviv University


Regulus Therapeutics

Relypsa

Reproductive Genetics Institute

Response Genetics

Rib-X Pharmaceuticals

Roche

Roquette

RTI Surgical

Rules-Based Medicine

RXi Pharmaceuticals

Sangamo BioSciences

Sanming Huajian Bioengineering









Sanofi-Aventis

Sanofi

Santaris

Sanyo

Schepens Eye Research Institute

Scripps Research Institute

Seattle Genetics

Servier

Shell Oil Company

Shell Oil Products

Shiva Biomedical

Sigma-Aldrich

Skyline Diagnostics

Solazyme-Roquette Nutritionals

Solazyme

Sorrento Therapeutics

Stanford University

Stemco Biomedical

SuperGen

Synthetic Blood International

Takeda Pharmaceutical

Targacept

Targeted Genetics

The Regents of the University of California

Therinject

ThermoGenesis

ThromboGenics

Transgenomic

Tranzyme Pharma

Trevena

Trius Therapeutics

TrovaGene

TTFactor

University of Cambridge

University of Colorado

University of Connecticut

University of Florida Research Foundation

University of Miami

University of Michigan

University of Minnesota

University of Missouri

University of Notre of Dame

University of Pennsylvania

University of Texas

University of Wuerzburg

Verastem

Verio Therapeutics

Virginia Commonwealth University









WA 32609

Wayne State University

Whitehead Institute

Wisconsin Alumni Research Foundation

Wyeth

Xencor

Xoma

Yale University

Zoetis

ZymoGenetics

9.3. By deal type

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Contract service

Co-promotion

CRADA

Cross-licensing

Development

Distribution

Equity purchase

Evaluation

Grant

Joint venture

Licensing

Litigation

Manufacturing

Marketing

Material transfer

Option

Promotion

Research

Settlement

Sub-license

Supply

Technology transfer

Termination

Warranty

9.4. By stage of development

Discovery

Formulation

Phase I









Phase II

Preclinical

9.5. By therapy area

Cardiovascular

Angina

Atherosclerosis

Congestive heart failure

Central Nervous System

Epilepsy

Pain

Parkinson's disease

Stroke

Dermatology

Gastrointestinal

Ulcerative colitis

Genetic disorders

Cystic Fibrosis (CF)

Huntington's disease

Genitourinary

Renal failure

Gynaecology

Hematology

Anemia

Hospital care

Orthopedics

Transplantation

Immunology

Inflammation

Infectives

Bacterial

Methicillin-resistant Staphylococcus aureus (MRSA)

Viral

Foot and mouth disease

B

C

HIV

Influenza

H1N1 (Swine Flu)

Metabolic

Cirrhosis

Diabetes

Type 2

Liver disease

Lysosomal storage disorders

Musculoskeletal

Rheumatoid arthritis









Muscular dystrophy

Spinal muscular atrophy

Obstetrics

Oncology

Bladder cancer

Brain cancer

Breast cancer

Colorectal cancer

Head and neck cancer

Leukemia

Acute myelogenous leukemia

Chronic lymphocytic leukemia

Liver cancer

Lung cancer

Lymphoma

Multiple myeloma

Ovarian cancer

Pancreatic cancer

Solid tumors

Ophthalmics

Age-related macular degeneration

Blindness

Diabetic macular edema

Glaucoma

Retinopathy

Psychiatry

Attention deficit hyperactivity disorder

Cognitive impairment

Alzheimers

Schizophrenia

Public health

Addiction

Obesity

Respiratory

Asthma

Chronic obstructive pulmonary disease

Pulmonary arterial hypertension

Chapter 10 ' Discovery stage dealmaking directory

10.1. Introduction

10.2. Deals by discovery stage

About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

Order Form ' Reports









Order Form ' Reports

Order Form ' Therapy Reports

View the accompanying volume for:

Appendices

Introduction

Appendix 1 ' Directory of discovery stage deals by company A-Z 2009-2013

Appendix 2 ' Directory of discovery stage deals by deal type 2009-2013

Appendix 3 ' Directory of discovery stage deals by therapy area 2009-2013

Appendix 4 ' Partnering resource center

Online partnering

Partnering events

Further reading on dealmaking

Table of figures

Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking

Figure 2: Agreements signed by phase of development (2009-2013), % of all deals where stage disclosed

Figure 3: Components of the pure licensing deal structure

Figure 4: Payment options for discovery stage partnering deals

Figure 5: Issues affecting royalty rates

Figure 6: Discovery stage partnering frequency 2009-2013

Figure 7: Big pharma ' top 50 ' discovery stage deals 2009 to 2013

Figure 8: Big pharma discovery stage deal frequency ' 2009 to 2013

Figure 9: Big biotech ' top 50 ' discovery stage deals 2009 to 2013

Figure 10: Big biotech discovery stage deal frequency ' 2009 to 2013

Figure 11: Discovery stage partnering by deal type since 2009

Figure 12: Discovery stage partnering by disease type since 2009

Figure 13: Discovery stage partnering by technology type since 2009

Figure 14: Review of median upfront payments for discovery stage deals

Figure 15: Review of median milestone payments for discovery stage deals

Figure 16: Review of median royalty payments for discovery stage deals






Figure 22: Discovery stage deal headline value distribution, US$million

Figure 23: Summary median headline value for discovery stage of development, 2009-2013


Figure 25: Discovery stage deals with upfront payment values' 2010












Figure 29: Discovery stage deal upfront payment distribution, US$million

Figure 30: Summary median upfront payments discovery stage of development, 2009-2013






Figure 36: Discovery stage deal milestone distribution, US$million

Figure 37: Summary median milestone payments for discovery stage of development, 2009-2014






Figure 43: Discovery stage deal royalty rate distribution, US$million

Figure 44: Summary median royalty rate for discovery stage of development, 2009-2013

Figure 45: Top discovery stage deals by value since 2009

Companies mentioned

Abbott

Actavis

Amgen

Astellas

AstraZeneca

Bayer

Biogen Idec



Celgene

CSL

Daiichi Sankyo

Eli Lilly

Fresenius

Fresenius Biotech

Gilead Sciences

GlaxoSmithKline

Johnson & Johnson

Kyowa Hakko Kirin

Lundbeck

Merck & Co

Merck KGaA

Merck KGaA

Merck Serono

Mitsubishi Tanabe

Novartis









Novo Nordisk

Otsuka

Pfizer

Roche

Sanofi

Servier

Shionogi

Takeda

Teva


Elan

Emergent BioSolutions

Galapagos

Genmab

LFB Group

Morphosys

Novo Nordisk

PDL BioPharma


Seattle Genetics

Spectrum Pharmaceuticals

Swedish Orphan Biovitrum

ADMA Biologics


Amgen

AstraZeneca

Avecia Biologics

AVEO Pharmaceuticals

Biotest



Cell Therapeutics

Centocor Ortho Biotech

Crucell

Cytodyn

Elan

Facet Biotechnology

GE Healthcare

Genzyme

GlycArt

Green Cross

ImmunoCellular Therapeutics

ImmunoGen

Intrexon

KaloBios Pharmaceuticals

Lonza

Lpath

Macrogenics









Massachusetts Biologic Laboratories

Medarex

Merrimack Pharmaceuticals

Micromet

Millennium

MorphoSys

Orbimed Advisors

Peregrine Pharmaceuticals

PharmAthene

Progenics Pharmaceuticals


Repligen

RIT Oncology

Stason Pharmaceuticals

Synthetic Biologics

Targepeutics

TrovaGene

TTFactor

University of Texas

Wyeth

Xencor

Xoma

ZymoGenetics








>> Get this Report Now by email!Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93

If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require.

Product Formats Please select the product formats and the quantity you require.

Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech

1 User License--USD 3 295.00 Quantity: _____

CD-ROM--USD 3 795.00 Quantity: _____

2-5 User License--USD 4 995.00 Quantity: _____

Site License--USD 9 895.00 Quantity: _____

Corporate License--USD 16 495.00 Quantity: _____








>> Get this Report Now by email!Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card

Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer

Crédit Mutuel

RIB : 10278 07314 00020257701 89

BIC : CMCIFR2A

IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check

UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at

http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93

Customer signature:







discovery stage partnering terms and agreements in pharma and biotech

Documents

discovery deals

leading discovery stage

review of discovery

deals terms

themajority of deals

contract documents available

triggered contract documents

agreement contract